Sprycel is approved for 2nd line treatment of CML. Sprycel has been developed for the treatment of patients with BCR-ABL-positive CML and acute lymphoblastic leukemia (ALL); for the treatment of patients who fail Gleevec. Sprycel is approved by the U.S. Food and Drug Administration for treatment of patients who fail or are intolerant to Gleeevec.
There rare several trial of this agent for lung cancer, for example:Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation, CT00858403 and Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC (TOP0801), NCT00787267 and others. At this time it looks like some apteints respond to this drug but the responsive subgroup needs to be better defined. A pashe II trial concluded: ” Dasatinib as a single agent has activity in a subset of patients with NSCLC.”
Borthakur G, Kantarjian HM, O/Brien SM, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Journal of Clinical Oncology. 2008;26:abstract 7013
J. M. Johnson, X. Tang, H. Tran, B. Saigal, J. Erasmus, J. Kurie, L. Hwang, Y. Oh, S. Lippman, D. J. Stewart; M. D. Anderson Cancer Center, Houston, TX; Fredrick Oncology Hematology Associates, Fredrick, MD Phase II study of dasatinib in non-small cell lung cancer (NSCLC).J Clin Oncol 27, 2009 (suppl; abstr e19015)